This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Assessing the Phase 3 ASTRO Trial Results for Subcutaneous TREMFYA Induction in Ulcerative Colitis

Ticker(s): JNJ

Who's the expert?

A gastroenterologist specializing in inflammatory bowel disease (IBD), with clinical trial experience and in-depth knowledge of IL-23 pathway inhibitors, induction and maintenance regimens in UC, and real-world treatment challenges for biologic-naïve and refractory patients.

Interview Questions
Q1.

At Week 24, over 35% of patients treated with SC TREMFYA® achieved clinical remission, compared to 9.4% on placebo. In clinical practice, how significant is this remission delta for treatment decision-making, and does it compare favorably with other biologics used in UC?

Added By: slingshot_insights
Q2.

TREMFYA is now positioned as the first IL-23 inhibitor to demonstrate success with a fully subcutaneous induction regimen. What impact might this convenience have on adherence and patient autonomy, especially in long-term disease management?

Added By: slingshot_insights
Q3.

The trial showed 40–45% endoscopic improvement in the TREMFYA® arms versus just 12% for placebo. From a mucosal healing standpoint, how predictive are these endoscopic outcomes of sustained disease control?

Added By: slingshot_insights
Q4.

Both 100 mg q8w and 200 mg q4w maintenance schedules showed similar efficacy. How important is having dosing flexibility post-induction in terms of customizing treatment plans for different patient profiles?

Added By: slingshot_insights
Q5.

REMFYA® showed statistically significant benefit across both biologic/JAK inhibitor-naïve and -refractory patients. What does this suggest about its mechanism and durability in patients with prior treatment failures?

Added By: slingshot_insights
Q6.

With safety outcomes in ASTRO aligning with the known profile of TREMFYA®, and additional liver monitoring requirements introduced in UC and CD, how manageable is this monitoring burden in routine care?

Added By: slingshot_insights
Q7.

Given that SC induction results mirrored those seen with IV induction in the QUASAR study, do you see SC induction eventually becoming the preferred standard, particularly in community settings or for self-administering patients?

Added By: slingshot_insights
Q8.

Assuming FDA approval of SC induction is granted, how quickly do you expect the SC option to be integrated into clinical practice, and what are the key hurdles for broader physician uptake and payer coverage?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained
178Days Left to Join Project

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.